News and Comments

THE TIME HAS COME FOR VALUING IMMNOGEN TECHNOLOGY AND PIPELINE PRODUCTS

  Saturday, October 26, 2013

Q3 Financial Results More...

COULD AGENUS VACCINE FOR GLIOBLASTOMA BE ASSIGNED BREAKTHROUGH DESIGNATION?

  Tuesday, September 17, 2013

AGENUS (AGEN) has extraordinary news. A recent analysis from a Phase 2 trial in patients with newly diagnosed glioblastoma multiforme (GBM) treated with Prophage Series G-100 (HSPPC-96) in combination with the current standard of care (radiation and temozolomide) showed an almost 18 month median progression free survival (PFS), which represents a 160% increase versus current standard of care alone. The results confirm continuation of the positive trends from the Phase 2 HSPPC-96 newly diagnosed GBM trial first reported at the 81st American Association of Neurological Surgeons (AANS) Annual Scientific Meeting in May 2013. More...

AGENUS OFFERS AN INVESTMENT OPPORTUNITY.

  Saturday, September 07, 2013

 More...

YES. GILEAD DID IT AGAIN

  Thursday, August 29, 2013

GILEAD DID IT AGAIN  More...

ARIAD: SUCCUMBING TEMPORARILY TO EXTRAORDINARY PRESSURE

  Friday, August 09, 2013

Ariad’s (ARIA) conference call and the discussions that followed confirmed our optimistic projections regarding Ariad’s leukemia drug Iclusig (ponatinib) sales. The announced exciting news, while is being met with a stock selloff, it cemented our conviction that Iclusig possesses all the features of a blockbuster and the criteria of growth, which are built through its efficacy derived from its mode of action. Iclusig has offered the oncology community a new option for hope in patients who, for a reason or another, cannot use the conventional first line treatments and those whose leukemia, or recurrent leukemia stopped responding to the currently used treatments. Although Iclusig is not officially designated a breakthrough, it is viewed as indispensable for the various kinds of leukemia it has been granted approval for, which is the main reason behind FDA granting it early approval.   More...

REGENERON'S HORSE EYELEA TRIPLES ITS SPEED

  Tuesday, August 06, 2013

Each and every time investors believed Regeneron (REGN) highest high value has been reached, like a magician, it pulled another chicken out of its long black hat and made it lay another golden egg. Regeneron’s new different egg is expected to boost its wealth, turning the current estimation upside down, i.e., from overvalued or fairly valued into undervalued.    More...

THREE SMALL BIOTECH FIRMS IN THE SPOTLIGHT

  Wednesday, July 31, 2013

Three biotechnology firms with market caps below $1billion have been recently put in the spotlight; SYNTA (SNTA) with a market cap of 535.54 million, ARRAY (ARRY) with a market cap of 774.22 million, and VANDA (VNDA) with a market cap of 320.45 million. More...

PERRIGO ACQUIRES ELAN

  Monday, July 29, 2013

Elan is Taken over by Perrigo in a transaction that involves cash and shares of Perrigo.  For the details of the transaction, the press release and the PDF presentation by the New Perrigo Prohost subscribers can click on TODAY'S HIGHLIGHTS at this Website.  More...

ILLUMINA AND THE FUTURE OF LIFE SCIENCES

  Wednesday, July 24, 2013

The moment some investors learned that ILLUMINA (ILMN) might acquire Advanced Liquid Logic (ALL), they debated selling the stock without knowing anything about the acquired firm or the advantages Illumina will add to its technological capability by acquiring it. Is this not the rule of thumb made possible by the power of computers’ programing? ILMN was already down anyway for the day, losing $0.95 during the bad NASDAQ day for the biotech sector in general. Long-term serious investors who are lured to sell ILMN must have felt bad when they heard the news after the end of Monday trading day.     More...

A GREAT DAY AND A GREAT FUTURE FOR ALNYLAM

  Thursday, July 11, 2013

A GREAT DAY AND A GREAT FUTURE FOR ALNYLAM  More...


Recent News_and_Comments


Archive


Tags